Polypeptide bulk supply DAMGO / 78123-71-4 pure powder
| DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR[1]. | |
| IC50 & Target | Kd: 3.46±0.84 nM (native μ-OPR)[1] |
|---|---|
| 体外研究 (In Vitro) | DAMGO, a μ-opioid receptor selective agonist, distinguishes between μ- and δ-opioid receptors around their first extracellular loops. In native μ-OPR, the Kd value for DAMGO is 3.46± 0.84 nM (n=3). The chimeric receptor MMDD, in which the carboxy-terminal half of μ-OPR is replaced with the corresponding region of δ-OPR, exhibits an equivalent affinity (Kd=2.13±0.40 nM; n=3) to DAMGO compared with the native μ-OPR[1]. DAMGO is a selective μ-opioid peptide. DAMGO abolishes the neuroprotective effect of CXCL12 in N-methyl-d-aspartate (NMDA) neurotoxicity studies. Regulation of neuronal response to CXCL12 is essential for shaping of developing and mature central nervous system (CNS). To establish whether DAMGO alter the effect of CXCL12 on neuronal survival, the ability of CXCL12 to protect neurons from N-methyl-d-aspartate (NMDA)-induced death is examined in the presence and absence of DAMGO. Cortical cultures are treated with DAMGO (1 and 10 μM). Neurons are subsequently exposed to NMDA (20 min) and/or CXCL12 (added 10 min before NMDA) in the absence of glia and then returned to the original culture dishes with the glial feeder layer. Neuronal death is evaluated after 24 h. DAMGO inhibits neuronal survival promoted by CXCL12[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 分子量 | 513.59 |
| Formula | C₂₆H₃₅N₅O₆ |
| CAS 号 | |
| Sequence | Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol |
| Sequence Shortening | Y-{d-Ala}-G-{Me-Phe}-G-ol |
Packing and Shipping:
Polypeptide bulk supply DAMGO / 78123-71-4 pure powder
| DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR[1]. | |
| IC50 & Target | Kd: 3.46±0.84 nM (native μ-OPR)[1] |
|---|---|
| 体外研究 (In Vitro) | DAMGO, a μ-opioid receptor selective agonist, distinguishes between μ- and δ-opioid receptors around their first extracellular loops. In native μ-OPR, the Kd value for DAMGO is 3.46± 0.84 nM (n=3). The chimeric receptor MMDD, in which the carboxy-terminal half of μ-OPR is replaced with the corresponding region of δ-OPR, exhibits an equivalent affinity (Kd=2.13±0.40 nM; n=3) to DAMGO compared with the native μ-OPR[1]. DAMGO is a selective μ-opioid peptide. DAMGO abolishes the neuroprotective effect of CXCL12 in N-methyl-d-aspartate (NMDA) neurotoxicity studies. Regulation of neuronal response to CXCL12 is essential for shaping of developing and mature central nervous system (CNS). To establish whether DAMGO alter the effect of CXCL12 on neuronal survival, the ability of CXCL12 to protect neurons from N-methyl-d-aspartate (NMDA)-induced death is examined in the presence and absence of DAMGO. Cortical cultures are treated with DAMGO (1 and 10 μM). Neurons are subsequently exposed to NMDA (20 min) and/or CXCL12 (added 10 min before NMDA) in the absence of glia and then returned to the original culture dishes with the glial feeder layer. Neuronal death is evaluated after 24 h. DAMGO inhibits neuronal survival promoted by CXCL12[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 分子量 | 513.59 |
| Formula | C₂₆H₃₅N₅O₆ |
| CAS 号 | |
| Sequence | Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol |
| Sequence Shortening | Y-{d-Ala}-G-{Me-Phe}-G-ol |
Packing and Shipping:
